HAVING secured up to £26.7m of funding from a FTSE-250 listed investment fund, Glass Pharms, the UK-based medical cannabis cultivation company, are delighted to...
GLASS Pharms has agreed a £22.5m funding deal to build the UK mainland’s first, high-THC, commercial cultivation facility for over 20 years.
The deal will...
PRESS RELEASE
FURTHER to the announcement dated 16 January 2023, Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on...